zicronapine
Small moleculeexperimental
Zicronapine is an atypical antipsychotic medication formerly under development by H. Lundbeck A/S. In phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to olanzapine. — Wikipedia
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2007 (NCT00768326)
Timeline
Indications
Studied for
Mechanism of action
- Dopamine D2 receptorINHIBITOR
DRD2 inhibitor
- Dopamine D1 receptorINHIBITOR
DRD1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CC1(C)C- Mol. weight
- 354.93 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaZicronapine ↗
- ChEMBLCHEMBL3039528 ↗
Also known as
- lu-31130
- lu-31130
- lu-31130
- zicronapine
- zicronapine
- zicronapine
- zicronapine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01377233 | Phase 2 | Jul 1, 2011 | Lundbeck |
| NCT01295372 | Phase 3 | Apr 1, 2011 | Lundbeck |
| NCT00770744 | Phase 2 | Sep 1, 2008 | Lundbeck |
| NCT00768326 | Phase 2 | Mar 1, 2007 | Lundbeck |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lundbeck | For profit | 4 | 4 | 2 | 2007 |
1 organizations
Page 1 / 1